



COUNTY OF SAN MATEO
Inter-Departmental Correspondence

San Mateo Medical Center

DATE: March 31, 2004

BOARD MEETING DATE: April 20, 2004

TO: Honorable Board of Supervisors

FROM: Nancy J. Steiger, Chief Executive Officer, San Mateo Medical Center *Y.S. P.S.*

SUBJECT: Acceptance of a Grant Award from Ingenix Pharmaceutical Services, Inc., for Bristol-Myers Squibb Company

Recommendation

1. Adopt a resolution accepting a grant from the Ingenix Pharmaceuticals Services, Inc. in the amount of \$30,780, and
2. Approve an Appropriation Transfer Request (ATR) to accept unanticipated revenue (\$6,156) for FY2003-04 and appropriate new revenue to Salaries and Benefits, and Service and Supplies (\$6,156).

Background

The Clinical Trials and Research Unit of the San Mateo Medical Center was established by the Health Services Agency in 2000 in order to provide a mechanism and infrastructure for the conduct of clinical treatment trials and medical or psychosocial research projects for the benefit of the residents of San Mateo County. A preliminary assessment by the Unit staff identified Hepatitis C as a problem affecting many of the County's patients with HIV. The Clinical Trials and Research Unit discovered that patients are not responding to the current drug treatments. This trial will evaluate patient's response to this new drug treatment.

Discussion

In January 2004 Ingenix Pharmaceutical Services, Inc. contacted the Clinical Trials and Research Unit to participate in a Multi-center Study for patients with HIV/AIDS. On January 14, 2004, the Ingenix Pharmaceutical Services, Inc. notified the County

that our site was selected to participate in the clinical trial. The County will receive \$6,156 for FY2003-04 and the remaining balance of \$24,624 in FY2004-05. The term of the agreement to conduct the study is February 20, 2004 through February 20, 2006

The primary purpose of this study is to assess the safety and effectiveness of 96-week treatment comparing Atazanavir/Ritonavir versus Lopinavir/Ritonavir, each in combination with Tenofovir and either Didanosine EC or Stavudine XR for patients with HIV/AIDS diagnosis.

Outcome Objectives

The following outcome objectives related to this project will be measured in 2004-2006 using an Evaluation Work Plan included in the grant proposal:

Outcome Measures (at end of first year)	2004-2006 Objectives
Percentage of project client goal (5 persons) recruited and assessed for this study.	100%
Percentage of project client's dosage comparisons completed for this study.	100%
Percentage of project clients with positive response to trial medications	75%

Vision Alignment

This agreement keeps the county's commitment of responsive, effective and collaborative government, and goal number 21, County employees understand, support and integrate the County vision and goals into their delivery of services. This agreement contributes to this commitment and goal by participating in a study to assess the safety and effectiveness of 96-week treatment comparing Atazanavir/Ritonavir versus Lopinavir/Ritonavir, each in combination with Tenofovir and either Didanosine EC or Stavudine XR for patients with HIV/AIDS diagnosis.

Fiscal Impact

The total amount of the award is \$30,780. The County will receive \$6,156 for FY 2003-2004. The anticipated additional funding of \$24,624 will be included in the Recommended Budget for FY2004-05. Administrative oversight, technical assistance, and project monitoring will be provided by existing Clinical Trials and Research staff. There is no net county cost associated with this project.